Skip to main content

Impfen bei Immundefizienz

Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen(I) Grundlagenpapier

Literatur

  1. 1.

    Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Hinweise zu Impfungen für Patienten mit Immundefizienz, Sonderdruck (2005).

  2. 2.

    Valour F, Cotte L, Voirin N, Godinot M, Ader F, Ferry T et al (2014) Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients. Vaccine 32(35:4558–4564

    Article  Google Scholar 

  3. 3.

    Grabmeier-Pfistershammer K, Herkner H, Touzeau-Roemer V, Rieger A, Burgmann H, Poeppl W (2015) Low tetanus, diphtheria and acellular pertussis (Tdap) vaccination coverage among HIV infected individuals in Austria. Vaccine 33(32):3929–3932

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Loubet P, Kerneis S, Groh M, Loulergue P, Blanche P, Verger P et al (2015) Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine 33(31):3703–3708

    Article  PubMed  Google Scholar 

  5. 5.

    Durham MD, Buchacz K, Armon C, Patel P, Wood K, Brooks JT (2011) Rates and correlates of influenza vaccination among HIV-infected adults in the HIV Outpatient Study (HOPS), USA, 1999-2008. Prev Med 53(1-2:89–94

    Article  Google Scholar 

  6. 6.

    Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M et al (2012) Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 130:S1–S24

    Article  PubMed  Google Scholar 

  7. 7.

    Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M et al (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58(3:309–318

    Article  Google Scholar 

  8. 8.

    Committee to Review Adverse Effects of V, Institute of M. In: Stratton K, Ford A, Rusch E, Clayton EW, editors. Adverse Effects of Vaccines: Evidence and Causality. Washington (DC): National Academies Press (US) Copyright 2012 by the National Academy of Sciences. All rights reserved.; 2011.

  9. 9.

    Fine PEM (1993) Herd immunity: history, theory, practice. Epidemiol Rev 15:265–302

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Anderson RM, May RM (1991) Infectious Diseases of Humans: Dynamics and Control. University Press, Oxford

    Google Scholar 

  11. 11.

    Ständigen Impfkommission (STIKO) am Robert Koch-Institut (2016) 2017. Epidemiol Bull 2016:34

    Google Scholar 

  12. 12.

    Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, Blaese RM et al (2014) Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol 133(4):961–966

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Esposito S, Prada E, Lelii M, Castellazzi L (2015) Immunization of children with secondary immunodeficiency. Hum Vaccin Immunother 11(11):2564–2570

    Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Principi N, Esposito S (2014) Vaccine use in primary immunodeficiency disorders. Vaccine 32(30):3725–3731

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H, Catherinot E et al (2014) Prevention of infections during primary immunodeficiency. Clin Infect Dis 59(10):1462–1470

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Farmand S, Baumann U, von Bernuth H, Borte M, Foerster-Waldl E, Franke K et al (2011) Interdisciplinary AWMF guideline for the diagnostics of primary immunodeficiency. Klin Padiatr 223(6):378–385

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG et al (2016) Trained immunity: A program of innate immune memory in health and disease. Science 352(6284):aaf1098

    Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Warfel JM, Edwards KM (2015) Pertussis vaccines and the challenge of inducing durable immunity. Curr Opin Immunol 35:48–54

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Pollard AJ, Perrett KP, Beverley PC (2009) Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 9(3):213–220

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Mitchell R, Kelly DF, Pollard AJ, Truck J (2014) Polysaccharide-specific B cell responses to vaccination in humans. Hum Vaccin Immunother 10(6):1661–1668

    Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    McKelvie B, Top K, McCusker C, Letenyi D, Issekutz TB, Issekutz AC (2014) Fatal pneumococcal meningitis in a 7-year-old girl with interleukin-1 receptor activated kinase deficiency (IRAK-4) despite prophylactic antibiotic and IgG responses to Streptococcus pneumoniae vaccines. J Clin Immunol 34(3):267–271

    Article  PubMed  Google Scholar 

  22. 22.

    Poolman J, Borrow R (2011) Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 10(3):307–322

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Remschmidt CHT, Wichmann O, Bogdan C, Falkenhorst G (2017) Effectiveness, immunogenicity and safety of revaccinations with the 23-valent pneumococcal polysaccharide vaccine in the elderly: a systematic review. Bmc Infect Dis 16(1):711

    Article  Google Scholar 

  24. 24.

    Falkenhorst GRC, Harder T, Wichmann O, Glodny S, Hummers-Pardier E, von Kries R, Weinke T, Ledig T, Bogdan C (2017) Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany. Bundesgesundheitsblatt 59(12):1623–1657

    Article  Google Scholar 

  25. 25.

    Kobrynski L (2015) Newborn screening for severe combined immune deficiency (technical and political aspects). Curr Opin Allergy Clin Immunol 15(6):539–546

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Buelow BJ, Verbsky JW, Routes JM (2016) Newborn screening for SCID: lessons learned. Expert Rev Hematol 9(6):579–584

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Siegrist CA, Aspinall R (2009) B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 9(3):185–194

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Newport MJ, Goetghebuer T, Weiss HA, Whittle H, Siegrist CA, Marchant A et al (2004) Genetic regulation of immune responses to vaccines in early life. Genes Immun 5(2):122–129

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Whaley MJ, Rose C, Martinez J, Laher G, Sammons DL, Smith JP et al (2010) Interlaboratory comparison of three multiplexed bead-based immunoassays for measuring serum antibodies to pneumococcal polysaccharides. Clin Vaccine Immunol 17(5):862–869

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Björkholm B, Bottiger M, Christenson B, Hagberg L (1986) Antitoxin antibody levels and the outcome of illness during an outbreak of diphtheria among alcoholics. Scand J Infect Dis 18(3):235-239

    Article  PubMed  Google Scholar 

  31. 31.

    Bigl S, Drechsler R (1997) Bestimmung von Diphterieantitoxin im Serum - ein Methodenvergleich. Mikrobiologie :93–95

  32. 32.

    Lumio JT et al (2003) What is a protective level of diphtheria antitoxin antibodies? Abstract 43rd Intersci Conf Antimicr Agents Chemother

  33. 33.

    Fiore AE, Finestone SM, Bell BP (2008) Vaccine, Elsevier, Philadelphia, S 177–203

    Google Scholar 

  34. 34.

    Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC (1999) What level of hepatitis B antibody is protective? J Infect Dis 179(2):489–492

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Kayhty H (1994) Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 22(4):397–402

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Zepp F, Schmitt HJ, Cleerbout J, Verstraeten T, Schuerman L, Jacquet JM (2009) Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 8(6):663–678

    CAS  Article  PubMed  Google Scholar 

  37. 37.

    Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR et al (1990) Measles antibody: reevaluation of protective titers. J Infect Dis 162(5):1036–1042

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Weibel RE, Buynak EB, McLean AA, Hilleman MR (1995) Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. Pediatrics 56:380–387

    Google Scholar 

  39. 39.

    Würzburg RU. http://www.meningococcus.uni-wuerzburg.de/startseite/leistungen/leistungen_meningokokken/. Zugegriffen: 12. Dezember 2016

  40. 40.

    MacNeil J, al. e (2015) Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. Morb Mortal Wkly Rep 64(41):1171–1176

    Article  Google Scholar 

  41. 41.

    Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Kayhty H et al (2003) Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21(23):3265–3272

    CAS  Article  PubMed  Google Scholar 

  42. 42.

    Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M et al (2007) Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 25(19):3816–3826

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL (1990) Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 162(6):1291–1297

    CAS  Article  PubMed  Google Scholar 

  44. 44.

    Matter L, Kogelschatz K, Germann D (1997) Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. J Infect Dis 175(4):749–755

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Sauerbrei A, Schafler A, Hofmann J, Schacke M, Gruhn B, Wutzler P (2012) Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test. Clin Vaccine Immunol 19(8):1261–1268

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Sauerbrei A, Farber I, Brandstadt A, Schacke M, Wutzler P (2004) Immunofluorescence test for sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent antibody to membrane antigen test. J Virol Methods 119(1):25–30

    CAS  Article  PubMed  Google Scholar 

  47. 47.

    Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P (1997) Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 20(5):381–383

    CAS  Article  PubMed  Google Scholar 

  48. 48.

    Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17(7):1055–1065

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Morillo-Gutierrez B, Worth A, Valappil M, Gaspar HB, Gennery AR (2015) Chronic Infection with Rotavirus Vaccine Strains in UK Children with Severe Combined Immunodeficiency. Pediatr Infect Dis J 34(9):1040–1041

    Article  PubMed  Google Scholar 

  50. 50.

    Perelygina L, Plotkin S, Russo P, Hautala T, Bonilla F, Ochs HD et al (2016) Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies. J Allergy Clin Immunol 138(5):1436–1439.e1

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Neven B, Perot P, Bruneau J, Pasquet M, Ramirez M, Diana JS et al (2017) Cutaneous and Visceral Chronic Granulomatous Disease Triggered by a Rubella Virus Vaccine Strain in Children With Primary Immunodeficiencies. Clin Infect Dis 64(1):83–86

    Article  PubMed  Google Scholar 

  52. 52.

    Bitnun A, Shannon P, Durward A, Rota PA, Bellini WJ, Graham C et al (1999) Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 29(4):855–861

    CAS  Article  PubMed  Google Scholar 

  53. 53.

    Iroh TP (2014) Measles vaccine strain from the skin rash of a DiGeorge patient receiving tumor necrosis factor inhibitor. Pediatr Infect Dis J 33(1):117

    Article  Google Scholar 

  54. 54.

    CDC (1996) Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep 45(28):603–606

    Google Scholar 

  55. 55.

    Leung J, Siegel S, Jones JF, Schulte C, Blog D, Schmid DS et al (2014) Fatal varicella due to the vaccine-strain varicella-zoster virus. Hum Vaccin Immunother 10(1):146–149

    Article  PubMed  Google Scholar 

  56. 56.

    Bayer DK, Martinez CA, Sorte HS, Forbes LR, Demmler-Harrison GJ, Hanson IC et al (2014) Vaccine-associated varicella and rubella infections in severe combined immunodeficiency with isolated CD4 lymphocytopenia and mutations in IL7R detected by tandem whole exome sequencing and chromosomal microarray. Clin Exp Immunol 178(3):459–469

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Dutmer CM, Asturias EJ, Smith C, Dishop MK, Schmid DS, Bellini WJ et al (2015) Late Onset Hypomorphic RAG2 Deficiency Presentation with Fatal Vaccine-Strain VZV Infection. J Clin Immunol 35(8):754–760

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  58. 58.

    Sabry A, Hauk PJ, Jing H, Su HC, Stence NV, Mirsky DM et al (2014) Vaccine strain varicella-zoster virus-induced central nervous system vasculopathy as the presenting feature of DOCK8 deficiency. J Allergy Clin Immunol 133(4):1225–1227

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Banovic T, Yanilla M, Simmons R, Robertson I, Schroder WA, Raffelt NC et al (2011) Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression. J Infect Dis 204(12):1893–1901

    CAS  Article  PubMed  Google Scholar 

  60. 60.

    Waters V, Peterson KS, LaRussa P (2007) Live viral vaccines in a DiGeorge syndrome patient. Arch Dis Child 92(6):519–520

    CAS  Article  PubMed  Google Scholar 

  61. 61.

    Schrauder A, Henke-Gendo C, Seidemann K, Sasse M, Cario G, Moericke A et al (2007) Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet 369(9568):1232

    Article  PubMed  Google Scholar 

  62. 62.

    Costa E, Buxton J, Brown J, Templeton KE, Breuer J, Johannessen I (2016) Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient. BMJ Case Rep. doi: 10.1136/bcr-2015-212688

  63. 63.

    Bhalla P, Forrest GN, Gershon M, Zhou Y, Chen J, LaRussa P et al (2015) Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation. Clin Infect Dis 60(7):1068–1074

    CAS  PubMed  Google Scholar 

  64. 64.

    Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y (2015) Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine 33(10):1235–1242

    Article  PubMed  Google Scholar 

  65. 65.

    de Silva R, Gunasena S, Ratnayake D, Wickremesinghe GD, Kumarasiri CD, Pushpakumara BA et al (2012) Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine 30(52):7561–7565

    Article  PubMed  Google Scholar 

  66. 66.

    Shaghaghi M, Parvaneh N, Ostad-Rahimi P, Fathi SM, Shahmahmoodi S, Abolhassani H et al (2014) Combined immunodeficiency presenting with vaccine-associated paralytic poliomyelitis: a case report and narrative review of literature. Immunol Invest 43(3):292–298

    Article  PubMed  Google Scholar 

  67. 67.

    Trimble R, Atkins J, Quigg TC, Burns CC, Wallace GS, Thomas M et al (2014) Vaccine-associated paralytic poliomyelitis and BCG-osis in an immigrant child with severe combined immunodeficiency syndrome - Texas, 2013. MMWR Morb Mortal Wkly Rep 63(33:721–724

    Google Scholar 

  68. 68.

    Canessa C, Romano F, Lippi F, Bianchi L, Kashef S, Rezaei N et al (2013) Bcgitis and vaccine-derived poliovirus infection in a patient with a novel deletion in RAG1 binding site. Int J Immunopathol Pharmacol 26(2):511–515

    CAS  Article  PubMed  Google Scholar 

  69. 69.

    Seligman SJ (2014) Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine 32(44):5769–5775

    Article  PubMed  Google Scholar 

  70. 70.

    Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T (2012) The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hyg 86(2):359–372

    Article  PubMed  PubMed Central  Google Scholar 

  71. 71.

    Monath TP (2012) Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 11(4):427–448

    CAS  Article  PubMed  Google Scholar 

  72. 72.

    Traiber C (2011) Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk. J Pediatr (Rio J) 87(3):269–272

    Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Niehues, T., Bogdan, C., Hecht, J. et al. Impfen bei Immundefizienz. Bundesgesundheitsbl 60, 674–684 (2017). https://doi.org/10.1007/s00103-017-2555-4

Download citation